

Xin Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2924328/publications.pdf>

Version: 2024-02-01

100
papers

4,927
citations

109321

35
h-index

114465

63
g-index

104
all docs

104
docs citations

104
times ranked

7180
citing authors

#	ARTICLE	IF	CITATIONS
1	Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients. <i>Journal of Cancer</i> , 2022, 13, 744-751.	2.5	10
2	Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. <i>Cell Research</i> , 2022, 32, 477-490.	12.0	101
3	P2X7/P2X4 Receptors Mediate Proliferation and Migration of Retinal Microglia in Experimental Glaucoma in Mice. <i>Neuroscience Bulletin</i> , 2022, 38, 901-915.	2.9	11
4	Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. <i>Molecular Cancer</i> , 2022, 21, 84.	19.2	34
5	The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. <i>Cell Metabolism</i> , 2022, 34, 581-594.e8.	16.2	105
6	<sc>RNA</sc> binding protein <sc>POP7</sc> regulates <sc>ILF3 mRNA</sc> stability and expression to promote breast cancer progression. <i>Cancer Science</i> , 2022, 113, 3801-3813.	3.9	6
7	In vivo multidimensional CRISPR screens identify <i>Lgals2</i> as an immunotherapy target in triple-negative breast cancer. <i>Science Advances</i> , 2022, 8, .	10.3	26
8	Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 884-892.	6.3	21
9	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. <i>Cell Research</i> , 2021, 31, 178-186.	12.0	146
10	Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. <i>Cell Metabolism</i> , 2021, 33, 51-64.e9.	16.2	211
11	Neuroprotective effect of the somatostatin receptor 5 agonist L-817,818 on retinal ganglion cells in experimental glaucoma. <i>Experimental Eye Research</i> , 2021, 204, 108449.	2.6	9
12	Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers. <i>Molecular Therapy</i> , 2021, 29, 2350-2365.	8.2	49
13	PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 5491-5505.	0.9	25
14	Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated $PI3K$ in early and advanced HER2-positive breast cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e589.	4.0	6
15	Interplay between M1/4ller cells and microglia aggravates retinal inflammatory response in experimental glaucoma. <i>Journal of Neuroinflammation</i> , 2021, 18, 303.	7.2	34
16	Dopamine D2 Receptor-Mediated Modulation of Rat Retinal Ganglion Cell Excitability. <i>Neuroscience Bulletin</i> , 2020, 36, 230-242.	2.9	11
17	Breast Cancer: IL1R2 Blockade Suppresses Breast Tumorigenesis and Progression by Impairing USP15-Dependent BMI1 Stability (Adv. Sci. 1/2020). <i>Advanced Science</i> , 2020, 7, 2070002.	11.2	0
18	Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation. <i>Cancer Medicine</i> , 2020, 9, 1903-1910.	2.8	10

#	ARTICLE	IF	CITATIONS
19	Modified lymph node ratio improves the prognostic predictive ability for breast cancer patients compared with other lymph node staging systems. <i>Breast</i> , 2020, 49, 93-100.	2.2	11
20	Tumor necrosis factor-alpha aggravates gliosis and inflammation of activated retinal MÄ¼ller cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 531, 383-389.	2.1	19
21	Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer. <i>Theranostics</i> , 2020, 10, 11092-11109.	10.0	22
22	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. <i>Nature Communications</i> , 2020, 11, 5679.	12.8	41
23	Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers. <i>Theranostics</i> , 2020, 10, 10531-10547.	10.0	27
24	The Burden and Trends of Breast Cancer From 1990 to 2017 at the Global, Regional, and National Levels: Results From the Global Burden of Disease Study 2017. <i>Frontiers in Oncology</i> , 2020, 10, 650.	2.8	56
25	Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. <i>Nucleic Acids Research</i> , 2020, 48, 3638-3656.	14.5	105
26	Association between socioeconomic factors at diagnosis and survival in breast cancer: A population-based study. <i>Cancer Medicine</i> , 2020, 9, 1922-1936.	2.8	28
27	Clinical features and survival of pregnancy-associated breast cancer: a retrospective study of 203 cases in China. <i>BMC Cancer</i> , 2020, 20, 244.	2.6	11
28	Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 574813.	2.8	13
29	Nomogram for Predicting Breast Cancer-Specific Mortality of Elderly Women with Breast Cancer. <i>Medical Science Monitor</i> , 2020, 26, e925210.	1.1	3
30	Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk. <i>Annals of Translational Medicine</i> , 2020, 8, 1417-1417.	1.7	7
31	KCNN4 induces multiple chemoresistance in breast cancer by regulating BCL2A1. <i>American Journal of Cancer Research</i> , 2020, 10, 3302-3315.	1.4	2
32	Integrative 3â€² Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 22-30.	3.7	13
33	Co-Expression Network Analysis Identified Gene Signatures in Osteosarcoma as a Predictive Tool for Lung Metastasis and Survival. <i>Journal of Cancer</i> , 2019, 10, 3706-3716.	2.5	49
34	High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer. <i>Cancer Cell International</i> , 2019, 19, 165.	4.1	24
35	Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells. <i>Oncogene</i> , 2019, 38, 5778-5791.	5.9	19
36	Downregulation of circRNA DMNT3B contributes to diabetic retinal vascular dysfunction through targeting miR-20b-5p and BAMBI. <i>EBioMedicine</i> , 2019, 49, 341-353.	6.1	123

#	ARTICLE	IF	CITATIONS
37	Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers. <i>Cell Research</i> , 2019, 29, 832-845.	12.0	31
38	Guide Positioning Sequencing identifies aberrant DNA methylation patterns that alter cell identity and tumor-immune surveillance networks. <i>Genome Research</i> , 2019, 29, 270-280.	5.5	25
39	Unveiling novel targets of paclitaxel resistance by single molecule long-read RNA sequencing in breast cancer. <i>Scientific Reports</i> , 2019, 9, 6032.	3.3	13
40	Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5002-5014.	7.0	269
41	Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 3658-3672.	7.0	31
42	Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. <i>Cancer Cell</i> , 2019, 35, 428-440.e5.	16.8	571
43	The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. <i>Science Advances</i> , 2019, 5, eaat9820.	10.3	95
44	Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT. <i>Nature Communications</i> , 2019, 10, 1637.	12.8	86
45	Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 2850-2860.	5.1	12
46	Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 225-237.	2.5	49
47	PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression. <i>Cancer Research</i> , 2018, 78, 3190-3206.	0.9	62
48	Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. <i>Nature Communications</i> , 2018, 9, 1357.	12.8	100
49	Elevated miR-301a expression indicates a poor prognosis for breast cancer patients. <i>Scientific Reports</i> , 2018, 8, 2225.	3.3	38
50	IL6 blockade potentiates the anti-tumor effects of β -secretase inhibitors in Notch3-expressing breast cancer. <i>Cell Death and Differentiation</i> , 2018, 25, 330-339.	11.2	38
51	Protein C receptor stimulates multiple signaling pathways in breast cancer cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 1413-1424.	3.4	23
52	Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study. <i>BMC Cancer</i> , 2018, 18, 1085.	2.6	16
53	Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5937-5950.	1.9	35
54	Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 5881-5894.	1.9	14

#	ARTICLE	IF	CITATIONS
55	No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 118, 928-935.	1.7	9
56	Development and Validation of Nomograms for Predicting Overall and Breast Cancer-Specific Survival in Young Women with Breast Cancer: A Population-Based Study. <i>Translational Oncology</i> , 2018, 11, 1334-1342.	3.7	10
57	MicroRNA-493 is a prognostic factor in triple-negative breast cancer. <i>Cancer Science</i> , 2018, 109, 2294-2301.	3.9	32
58	CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription. <i>Theranostics</i> , 2018, 8, 2549-2564.	10.0	44
59	Survival following breast-conserving therapy is equal to that following mastectomy in young women with early-stage invasive lobular carcinoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1703-1707.	1.0	9
60	Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. <i>Cancer Medicine</i> , 2018, 7, 4156-4169.	2.8	34
61	Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer. <i>Scientific Reports</i> , 2017, 7, 1134.	3.3	5
62	Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. <i>Scientific Reports</i> , 2017, 7, 45411.	3.3	149
63	The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. <i>International Journal of Cancer</i> , 2017, 141, 129-142.	5.1	89
64	High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 1002-1011.	1.4	7
65	High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 64900-64909.	1.8	41
66	Positive expression of miR-361-5p indicates better prognosis for breast cancer patients. <i>Journal of Thoracic Disease</i> , 2016, 8, 1772-1779.	1.4	34
67	Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People's Republic of China. <i>OncoTargets and Therapy</i> , 2016, 9, 2287.	2.0	11
68	Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway. <i>OncoTargets and Therapy</i> , 2016, 9, 1801.	2.0	45
69	The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis. <i>Cancer Letters</i> , 2016, 377, 87-96.	7.2	32
70	Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex. <i>Cell</i> , 2016, 165, 331-342.	28.9	163
71	Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 33.	5.0	176
72	Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4859-4869.	7.0	60

#	ARTICLE	IF	CITATIONS
73	Clinicopathological Characteristics and Survival Outcomes in Invasive Papillary Carcinoma of the Breast: A SEER Population-Based Study. <i>Scientific Reports</i> , 2016, 6, 24037.	3.3	17
74	Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1653-1662.	7.0	68
75	Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. <i>Cancer Research</i> , 2016, 76, 2105-2114.	0.9	168
76	SSBP1 Suppresses TGF β -Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling. <i>Cancer Research</i> , 2016, 76, 952-964.	0.9	59
77	Loss of TIM50 suppresses proliferation and induces apoptosis in breast cancer. <i>Tumor Biology</i> , 2016, 37, 1279-1287.	1.8	22
78	The 3'UTR signature defines a highly metastatic subgroup of triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 59834-59844.	1.8	32
79	Genetic evaluation of BRCA1-A complex genes with triple-negative breast cancer susceptibility in Chinese women. <i>Oncotarget</i> , 2016, 7, 9759-9772.	1.8	3
80	The BMP inhibitor DAND5 in serum predicts poor survival in breast cancer. <i>Oncotarget</i> , 2016, 7, 14951-14962.	1.8	10
81	Elevated expression of RNA methyltransferase BCDIN3D predicts poor prognosis in breast cancer. <i>Oncotarget</i> , 2016, 7, 53895-53902.	1.8	18
82	In-line phase-contrast and grating-based phase-contrast synchrotron imaging study of brain micrometastasis of breast cancer. <i>Scientific Reports</i> , 2015, 5, 9418.	3.3	22
83	Deregulation of RGS17 Expression Promotes Breast Cancer Progression. <i>Journal of Cancer</i> , 2015, 6, 767-775.	2.5	18
84	Down-Regulation of NDUF9 Promotes Breast Cancer Cell Proliferation, Metastasis by Mediating Mitochondrial Metabolism. <i>PLoS ONE</i> , 2015, 10, e0144441.	2.5	46
85	Identification of a Comprehensive Spectrum of Genetic Factors for Hereditary Breast Cancer in a Chinese Population by Next-Generation Sequencing. <i>PLoS ONE</i> , 2015, 10, e0125571.	2.5	44
86	Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. <i>Oncotarget</i> , 2015, 6, 22985-22995.	1.8	16
87	Expression of autophagy-related proteins ATG5 and FIP200 predicts favorable disease-free survival in patients with breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 816-822.	2.1	27
88	Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. <i>Cancer Research</i> , 2015, 75, 1504-1515.	0.9	71
89	High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0140572.	2.5	48
90	Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF β /SMAD signaling. <i>Oncotarget</i> , 2015, 6, 16352-16365.	1.8	42

#	ARTICLE	IF	CITATIONS
91	Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients. <i>Oncotarget</i> , 2015, 6, 22227-22238.	1.8	37
92	Loss of COX5B inhibits proliferation and promotes senescence via mitochondrial dysfunction in breast cancer. <i>Oncotarget</i> , 2015, 6, 43363-43374.	1.8	26
93	Prognostic Value of Myeloid Differentiation Primary Response 88 and Toll-Like Receptor 4 in Breast Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e111639.	2.5	27
94	ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression. <i>OncoTargets and Therapy</i> , 2014, 7, 1083.	2.0	13
95	Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA-MB-231 cells. <i>Oncology Letters</i> , 2014, 8, 2086-2092.	1.8	9
96	Clinico-Pathological Features and Prognosis of Invasive Micropapillary Carcinoma Compared to Invasive Ductal Carcinoma: A Population-Based Study from China. <i>PLoS ONE</i> , 2014, 9, e101390.	2.5	30
97	An Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Favorable Response and Prognosis in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e111886.	2.5	95
98	A recessive variant of <i>XRCC4</i> predisposes to non- <i>BRCA1/2</i> breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. <i>Oncotarget</i> , 2014, 5, 12218-12232.	1.8	5
99	Ciliary neurotrophic factor receptor β subunit-modulated multiple downstream signaling pathways in hepatic cancer cell lines and their biological implications. <i>Hepatology</i> , 2008, 47, 1298-1308.	7.3	19
100	Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status. <i>Oncotarget</i> , 0, 7, 41285-41293.	1.8	47